Cell-cell fusion as a means to establish pluripotency.

J T Do, H R Schöler
{"title":"Cell-cell fusion as a means to establish pluripotency.","authors":"J T Do,&nbsp;H R Schöler","doi":"10.1007/3-540-31437-7_4","DOIUrl":null,"url":null,"abstract":"<p><p>Embryonic stem cells (ESCs), embryonic germ cells (EGCs), and embryonic carcinoma cells (ECCs) are three types of pluripotent cells derived from mammalian embryos. The three cell types are capable not only of self-renewal, but also of having the potential to give rise to cells of all tissue types in the fetal and adult body. In several reports, ESCs, ECCs, and EGCs have been described to reprogram somatic cells in vitro. After reprogramming caused by fusion, somatic cells exhibit various features of pluripotent cells: expression of pluripotency markers (e.g., Oct4, nanog, and Rex-1), absence of tissue-specific gene expression, reactivation of inactive X chromosome of female somatic cells, demethylation, as well as histone modification. An activity in pluripotent stem cells appears to be capable of inducing the global changes inherent in the reprogramming of somatic cells. Investigations involving pluripotent stem cells will yield substantial insight into various fundamental biological processes, such as cellular differentiation and de-differentiation. Most importantly for the public, however, is that such studies might lead into cell-based therapies and as such have the potential to change regenerative medicine.</p>","PeriodicalId":80277,"journal":{"name":"Ernst Schering Research Foundation workshop","volume":" 60","pages":"35-45"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/3-540-31437-7_4","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ernst Schering Research Foundation workshop","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/3-540-31437-7_4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22

Abstract

Embryonic stem cells (ESCs), embryonic germ cells (EGCs), and embryonic carcinoma cells (ECCs) are three types of pluripotent cells derived from mammalian embryos. The three cell types are capable not only of self-renewal, but also of having the potential to give rise to cells of all tissue types in the fetal and adult body. In several reports, ESCs, ECCs, and EGCs have been described to reprogram somatic cells in vitro. After reprogramming caused by fusion, somatic cells exhibit various features of pluripotent cells: expression of pluripotency markers (e.g., Oct4, nanog, and Rex-1), absence of tissue-specific gene expression, reactivation of inactive X chromosome of female somatic cells, demethylation, as well as histone modification. An activity in pluripotent stem cells appears to be capable of inducing the global changes inherent in the reprogramming of somatic cells. Investigations involving pluripotent stem cells will yield substantial insight into various fundamental biological processes, such as cellular differentiation and de-differentiation. Most importantly for the public, however, is that such studies might lead into cell-based therapies and as such have the potential to change regenerative medicine.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
细胞-细胞融合作为建立多能性的手段。
胚胎干细胞(ESCs)、胚胎生殖细胞(EGCs)和胚胎癌细胞(ECCs)是来源于哺乳动物胚胎的三种多能细胞。这三种类型的细胞不仅能够自我更新,而且有可能在胎儿和成人体内产生所有组织类型的细胞。在一些报道中,ESCs, ECCs和EGCs已经被描述为体外体细胞重编程。体细胞经过融合引起的重编程后,表现出多能性细胞的各种特征:多能性标记物(如Oct4、nanog和Rex-1)的表达,缺乏组织特异性基因的表达,女性体细胞无活性X染色体的再激活,去甲基化,以及组蛋白修饰。多能干细胞中的一种活性似乎能够诱导体细胞重编程中固有的全局变化。涉及多能干细胞的研究将对各种基本生物学过程产生实质性的见解,例如细胞分化和去分化。然而,对公众来说最重要的是,这些研究可能会导致基于细胞的疗法,因此有可能改变再生医学。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Experiences with dose finding in patients in early drug development: the use of biomarkers in early decision making. Genotype and phenotype relationship in drug metabolism. Clinical trials in elderly patients. Dose finding in pediatric patients. Integration of pediatric aspects into the general drug development process.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1